-
1
-
-
84861033763
-
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: towards a molecular classification with implications for targeted therapeutic interventions
-
Agathangelidis, A., Darzentas, N., Hadzidimitriou, A., Brochet, X., Murray, F., Yan, X.J., Davis, Z., van Gastel-Mol, E.J., Tresoldi, C., Chu, C.C., Cahill, N., Giudicelli, V., Tichy, B., Pedersen, L.B., Foroni, L., Bonello, L., Janus, A., Smedby, K., Anagnostopoulos, A., Merle-Beral, H., Laoutaris, N., Juliusson, G., di Celle, P.F., Pospisilova, S., Jurlander, J., Geisler, C., Tsaftaris, A., Lefranc, M.-P., Langerak, A.W., Oscier, D.G., Chiorazzi, N., Belessi, C., Davi, F., Rosenquist, R., Ghia, P. & Stamatopoulos, K. (2012) Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: towards a molecular classification with implications for targeted therapeutic interventions. Blood, 119, 4467-4475.
-
(2012)
Blood
, vol.119
, pp. 4467-4475
-
-
Agathangelidis, A.1
Darzentas, N.2
Hadzidimitriou, A.3
Brochet, X.4
Murray, F.5
Yan, X.J.6
Davis, Z.7
van Gastel-Mol, E.J.8
Tresoldi, C.9
Chu, C.C.10
Cahill, N.11
Giudicelli, V.12
Tichy, B.13
Pedersen, L.B.14
Foroni, L.15
Bonello, L.16
Janus, A.17
Smedby, K.18
Anagnostopoulos, A.19
Merle-Beral, H.20
Laoutaris, N.21
Juliusson, G.22
di Celle, P.F.23
Pospisilova, S.24
Jurlander, J.25
Geisler, C.26
Tsaftaris, A.27
Lefranc, M.-P.28
Langerak, A.W.29
Oscier, D.G.30
Chiorazzi, N.31
Belessi, C.32
Davi, F.33
Rosenquist, R.34
Ghia, P.35
Stamatopoulos, K.36
more..
-
2
-
-
79953072637
-
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
-
Badoux, X.C., Keating, M.J., Wang, X., O'Brien, S.M., Ferrajoli, A., Faderl, S., Burger, J., Koller, C., Lerner, S., Kantarjian, H. & Wierda, W.G. (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood, 117, 3016-3024.
-
(2011)
Blood
, vol.117
, pp. 3016-3024
-
-
Badoux, X.C.1
Keating, M.J.2
Wang, X.3
O'Brien, S.M.4
Ferrajoli, A.5
Faderl, S.6
Burger, J.7
Koller, C.8
Lerner, S.9
Kantarjian, H.10
Wierda, W.G.11
-
3
-
-
84875451856
-
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia
-
Badoux, X.C., Keating, M.J., Wen, S., Wierda, W.G., O'Brien, S.M., Faderl, S., Sargent, R., Burger, J.A. & Ferrajoli, A. (2012) Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 31, 584-591.
-
(2012)
Journal of Clinical Oncology
, vol.31
, pp. 584-591
-
-
Badoux, X.C.1
Keating, M.J.2
Wen, S.3
Wierda, W.G.4
O'Brien, S.M.5
Faderl, S.6
Sargent, R.7
Burger, J.A.8
Ferrajoli, A.9
-
4
-
-
27144548424
-
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
-
German CLL Study Group
-
Bergmann, M.A., Goebeler, M.E., Herold, M., Emmerich, B., Wilhelm, M., Ruelfs, C., Boening, L., Hallek, M.J. & German CLL Study Group (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica, 90, 1357-1364.
-
(2005)
Haematologica
, vol.90
, pp. 1357-1364
-
-
Bergmann, M.A.1
Goebeler, M.E.2
Herold, M.3
Emmerich, B.4
Wilhelm, M.5
Ruelfs, C.6
Boening, L.7
Hallek, M.J.8
-
5
-
-
84865861478
-
Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia
-
Billard, C. (2012) Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia. Leukemia, 26, 2032-2038.
-
(2012)
Leukemia
, vol.26
, pp. 2032-2038
-
-
Billard, C.1
-
6
-
-
84859719803
-
Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): final results of a multicenter phase ii trial on behalf of the Spanish CLL Study Group (GELLC)
-
Bosch, F., Abrisqueta, P., Villamor, N., Terol, M.J., González-Barca, E., González, M., Ferra, C., Abella, E., Delgado, J., García-Marco, J.A., Gonzalez, Y., Carbonell, F., Ferrer, S., Monzo, E., Jarque, I., Muntañola, A., Constants, M., Escoda, L. & Montserrat, E. (2011) Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): final results of a multicenter phase ii trial on behalf of the Spanish CLL Study Group (GELLC). Blood (ASH Annual Meeting Abstracts), 118, 293.
-
(2011)
Blood (ASH Annual Meeting Abstracts)
, vol.118
, pp. 293
-
-
Bosch, F.1
Abrisqueta, P.2
Villamor, N.3
Terol, M.J.4
González-Barca, E.5
González, M.6
Ferra, C.7
Abella, E.8
Delgado, J.9
García-Marco, J.A.10
Gonzalez, Y.11
Carbonell, F.12
Ferrer, S.13
Monzo, E.14
Jarque, I.15
Muntañola, A.16
Constants, M.17
Escoda, L.18
Montserrat, E.19
-
7
-
-
84873567955
-
Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
-
Brown, J.R., Kim, H.T., Armand, P., Cutler, C., Fisher, D.C., Ho, V., Koreth, J., Ritz, J., Wu, C., Antin, J.H., Soiffer, R.J., Gribben, J.G. & Alyea, E.P. (2012) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia, 27, 362-369.
-
(2012)
Leukemia
, vol.27
, pp. 362-369
-
-
Brown, J.R.1
Kim, H.T.2
Armand, P.3
Cutler, C.4
Fisher, D.C.5
Ho, V.6
Koreth, J.7
Ritz, J.8
Wu, C.9
Antin, J.H.10
Soiffer, R.J.11
Gribben, J.G.12
Alyea, E.P.13
-
8
-
-
84889100379
-
Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL
-
abstract 7003
-
Brown, J.R., Furman, R.R., Flinn, I., Coutre, S.E., Wagner-Johnston, N.D., Kahl, B.S., Spurgeon, S.E.F., Benson, D.M., Peterman, S., Johnson, D.M., Li, D., Dansey, R.D., Jahn, T.M. & Byrd, J.C. (2013) Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. Journal of Clinical Oncology (Meeting Abstracts), 31(Suppl), abstract 7003.
-
(2013)
Journal of Clinical Oncology (Meeting Abstracts)
, vol.31
, Issue.SUPPL
-
-
Brown, J.R.1
Furman, R.R.2
Flinn, I.3
Coutre, S.E.4
Wagner-Johnston, N.D.5
Kahl, B.S.6
Spurgeon, S.E.F.7
Benson, D.M.8
Peterman, S.9
Johnson, D.M.10
Li, D.11
Dansey, R.D.12
Jahn, T.M.13
Byrd, J.C.14
-
9
-
-
33749054253
-
Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT
-
Bruzzi, J.F., Macapinlac, H., Tsimberidou, A.M., Truong, M.T., Keating, M.J., Marom, E.M. & Munden, R.F. (2006) Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. Journal of Nuclear Medicine, 47, 1267-1273.
-
(2006)
Journal of Nuclear Medicine
, vol.47
, pp. 1267-1273
-
-
Bruzzi, J.F.1
Macapinlac, H.2
Tsimberidou, A.M.3
Truong, M.T.4
Keating, M.J.5
Marom, E.M.6
Munden, R.F.7
-
10
-
-
0036721489
-
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
-
Buggins, A.G.S., Mufti, G.J., Salisbury, J., Codd, J., Westwood, N., Arno, M., Fishlock, K., Pagliuca, A. & Devereux, S. (2002) Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood, 100, 1715-1720.
-
(2002)
Blood
, vol.100
, pp. 1715-1720
-
-
Buggins, A.G.S.1
Mufti, G.J.2
Salisbury, J.3
Codd, J.4
Westwood, N.5
Arno, M.6
Fishlock, K.7
Pagliuca, A.8
Devereux, S.9
-
11
-
-
77957366071
-
Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription
-
Buggins, A.G.S., Pepper, C., Patten, P.E.M., Hewamana, S., Gohil, S., Moorhead, J., Folarin, N., Yallop, D., Thomas, N.S.B., Mufti, G.J., Fegan, C. & Devereux, S. (2010) Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Research, 70, 7523-7533.
-
(2010)
Cancer Research
, vol.70
, pp. 7523-7533
-
-
Buggins, A.G.S.1
Pepper, C.2
Patten, P.E.M.3
Hewamana, S.4
Gohil, S.5
Moorhead, J.6
Folarin, N.7
Yallop, D.8
Thomas, N.S.B.9
Mufti, G.J.10
Fegan, C.11
Devereux, S.12
-
12
-
-
79959856063
-
Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9
-
Buggins, A.G.S., Levi, A., Gohil, S., Fishlock, K., Patten, P.E.M., Calle, Y., Yallop, D. & Devereux, S. (2011) Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. British Journal of Haematology, 154, 216-222.
-
(2011)
British Journal of Haematology
, vol.154
, pp. 216-222
-
-
Buggins, A.G.S.1
Levi, A.2
Gohil, S.3
Fishlock, K.4
Patten, P.E.M.5
Calle, Y.6
Yallop, D.7
Devereux, S.8
-
13
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., Heerema, N.A., Johnson, A.J., Sukbuntherng, J., Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., James, D.F. & O'Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369, 34-42.
-
(2013)
New England Journal of Medicine
, vol.369
, pp. 34-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
Flinn, I.W.4
Burger, J.A.5
Blum, K.A.6
Grant, B.7
Sharman, J.P.8
Coleman, M.9
Wierda, W.G.10
Jones, J.A.11
Zhao, W.12
Heerema, N.A.13
Johnson, A.J.14
Sukbuntherng, J.15
Chang, B.Y.16
Clow, F.17
Hedrick, E.18
Buggy, J.J.19
James, D.F.20
O'Brien, S.21
more..
-
14
-
-
56249095457
-
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
-
Castro, J.E., Sandoval-Sus, J.D., Bole, J., Rassenti, L. & Kipps, T.J. (2008) Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia, 22, 2048-2053.
-
(2008)
Leukemia
, vol.22
, pp. 2048-2053
-
-
Castro, J.E.1
Sandoval-Sus, J.D.2
Bole, J.3
Rassenti, L.4
Kipps, T.J.5
-
15
-
-
34447530283
-
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
-
Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R., Pettitt, A., Hamblin, T., Milligan, D., Child, J., Hamilton, M., Dearden, C., Smith, A., Bosanquet, A., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370, 230-239.
-
(2007)
Lancet
, vol.370
, pp. 230-239
-
-
Catovsky, D.1
Richards, S.2
Matutes, E.3
Oscier, D.4
Dyer, M.5
Bezares, R.6
Pettitt, A.7
Hamblin, T.8
Milligan, D.9
Child, J.10
Hamilton, M.11
Dearden, C.12
Smith, A.13
Bosanquet, A.14
Davis, Z.15
Brito-Babapulle, V.16
Else, M.17
Wade, R.18
Hillmen, P.19
-
16
-
-
33947243663
-
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study
-
Chanan-Khan, A., Miller, K.C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C.W., Goodrich, D.W., Bernstein, Z.P., Wallace, P., Spaner, D., Mohr, A., Byrne, C., Hernandez-Ilizaliturri, F., Chrystal, C., Starostik, P. & Czuczman, M.S. (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology, 24, 5343-5349.
-
(2006)
Journal of Clinical Oncology
, vol.24
, pp. 5343-5349
-
-
Chanan-Khan, A.1
Miller, K.C.2
Musial, L.3
Lawrence, D.4
Padmanabhan, S.5
Takeshita, K.6
Porter, C.W.7
Goodrich, D.W.8
Bernstein, Z.P.9
Wallace, P.10
Spaner, D.11
Mohr, A.12
Byrne, C.13
Hernandez-Ilizaliturri, F.14
Chrystal, C.15
Starostik, P.16
Czuczman, M.S.17
-
17
-
-
77952965028
-
Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin
-
Chu, C.C., Catera, R., Zhang, L., Didier, S., Agagnina, B.M., Damle, R.N., Kaufman, M.S., Kolitz, J.E., Allen, S.L., Rai, K.R. & Chiorazzi, N. (2010) Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood, 115, 3907-3915.
-
(2010)
Blood
, vol.115
, pp. 3907-3915
-
-
Chu, C.C.1
Catera, R.2
Zhang, L.3
Didier, S.4
Agagnina, B.M.5
Damle, R.N.6
Kaufman, M.S.7
Kolitz, J.E.8
Allen, S.L.9
Rai, K.R.10
Chiorazzi, N.11
-
18
-
-
84871427640
-
Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8-protocol of the German CLL Study Group (GCLLSG)
-
Cramer, P., Fink, A.M., Busch, R., Eichhorst, B., Wendtner, C.-M., Pflug, N., Schubert, F., Döhner, H., Rieger, M., Kneba, M., Mayer, J., Hallek, M. & Fischer, K. (2011) Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8-protocol of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts), 118, 2863.
-
(2011)
Blood (ASH Annual Meeting Abstracts)
, vol.118
, pp. 2863
-
-
Cramer, P.1
Fink, A.M.2
Busch, R.3
Eichhorst, B.4
Wendtner, C.-M.5
Pflug, N.6
Schubert, F.7
Döhner, H.8
Rieger, M.9
Kneba, M.10
Mayer, J.11
Hallek, M.12
Fischer, K.13
-
19
-
-
37049023065
-
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential
-
Deaglio, S., Vaisitti, T., Aydin, S., Bergui, L., D'Arena, G., Bonello, L., Omede, P., Scatolini, M., Jaksic, O., Chiorino, G., Efremov, D. & Malavasi, F. (2007) CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood, 110, 4012-4021.
-
(2007)
Blood
, vol.110
, pp. 4012-4021
-
-
Deaglio, S.1
Vaisitti, T.2
Aydin, S.3
Bergui, L.4
D'Arena, G.5
Bonello, L.6
Omede, P.7
Scatolini, M.8
Jaksic, O.9
Chiorino, G.10
Efremov, D.11
Malavasi, F.12
-
21
-
-
41349122438
-
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
-
UK National Cancer Research Institute NCRI, Haematological Oncology Clinical Studies Group & NCRI CLL Working Group
-
Dearden, C., Wade, R., Else, M., Richards, S., Milligan, D., Hamblin, T., Catovsky, D., UK National Cancer Research Institute NCRI, Haematological Oncology Clinical Studies Group & NCRI CLL Working Group (2008) The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood, 111, 1820-1826.
-
(2008)
Blood
, vol.111
, pp. 1820-1826
-
-
Dearden, C.1
Wade, R.2
Else, M.3
Richards, S.4
Milligan, D.5
Hamblin, T.6
Catovsky, D.7
-
22
-
-
37549046061
-
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
-
Del Poeta, G., Del Principe, M.I., Buccisano, F., Maurillo, L., Capelli, G., Luciano, F., Perrotti, A.P., Degan, M., Venditti, A., de Fabritiis, P., Gattei, V. & Amadori, S. (2008) Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer, 112, 119-128.
-
(2008)
Cancer
, vol.112
, pp. 119-128
-
-
Del Poeta, G.1
Del Principe, M.I.2
Buccisano, F.3
Maurillo, L.4
Capelli, G.5
Luciano, F.6
Perrotti, A.P.7
Degan, M.8
Venditti, A.9
de Fabritiis, P.10
Gattei, V.11
Amadori, S.12
-
23
-
-
70350475037
-
Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?
-
Delgado, J., Milligan, D.W. & Dreger, P. (2009) Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood, 114, 2581-2588.
-
(2009)
Blood
, vol.114
, pp. 2581-2588
-
-
Delgado, J.1
Milligan, D.W.2
Dreger, P.3
-
24
-
-
0344729013
-
Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia
-
Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreyfus, B., Binet, J.L. & Travade, P. (1998) Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. New England Journal of Medicine, 338, 1506-1514.
-
(1998)
New England Journal of Medicine
, vol.338
, pp. 1506-1514
-
-
Dighiero, G.1
Maloum, K.2
Desablens, B.3
Cazin, B.4
Navarro, M.5
Leblay, R.6
Leporrier, M.7
Jaubert, J.8
Lepeu, G.9
Dreyfus, B.10
Binet, J.L.11
Travade, P.12
-
25
-
-
0028987180
-
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
-
Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J. & Stilgenbauer, S. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
-
(1995)
Blood
, vol.85
, pp. 1580-1589
-
-
Dohner, H.1
Fischer, K.2
Bentz, M.3
Hansen, K.4
Benner, A.5
Cabot, G.6
Diehl, D.7
Schlenk, R.8
Coy, J.9
Stilgenbauer, S.10
-
26
-
-
33845543049
-
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
-
Chronic Leukemia Working Party of the EBMT
-
Dreger, P., Corradini, P., Kimby, E., Michallet, M., Milligan, D., Schetelig, J., Wiktor-Jedrzejczak, W., Niederwieser, D., Hallek, M., Montserrat, E. & Chronic Leukemia Working Party of the EBMT (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia, 21, 12-17.
-
(2007)
Leukemia
, vol.21
, pp. 12-17
-
-
Dreger, P.1
Corradini, P.2
Kimby, E.3
Michallet, M.4
Milligan, D.5
Schetelig, J.6
Wiktor-Jedrzejczak, W.7
Niederwieser, D.8
Hallek, M.9
Montserrat, E.10
-
27
-
-
77957743452
-
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
-
for the German CLL Study Group
-
Dreger, P., Döhner, H., Ritgen, M., Böttcher, S., Busch, R., Dietrich, S., Bunjes, D., Cohen, S., Schubert, J., Hegenbart, U., Beelen, D., Zeis, M., Stadler, M., Hasenkamp, J., Uharek, L., Scheid, C., Humpe, A., Zenz, T., Winkler, D., Hallek, M., Kneba, M., Schmitz, N. & Stilgenbauer, S. for the German CLL Study Group (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 116, 2438-2447.
-
(2010)
Blood
, vol.116
, pp. 2438-2447
-
-
Dreger, P.1
Döhner, H.2
Ritgen, M.3
Böttcher, S.4
Busch, R.5
Dietrich, S.6
Bunjes, D.7
Cohen, S.8
Schubert, J.9
Hegenbart, U.10
Beelen, D.11
Zeis, M.12
Stadler, M.13
Hasenkamp, J.14
Uharek, L.15
Scheid, C.16
Humpe, A.17
Zenz, T.18
Winkler, D.19
Hallek, M.20
Kneba, M.21
Schmitz, N.22
Stilgenbauer, S.23
more..
-
28
-
-
84861498523
-
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial
-
Dreger, P., Dohner, H., McClanahan, F., Busch, R., Ritgen, M., Greinix, H., Fink, A.-M., Knauf, W., Stadler, M., Pfreundschuh, M., Duhrsen, U., Brittinger, G., Hensel, M., Schetelig, J., Winkler, D., Buhler, A., Kneba, M., Schmitz, N., Hallek, M. & Stilgenbauer, S. (2012) Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial. Blood, 119, 4851-4859.
-
(2012)
Blood
, vol.119
, pp. 4851-4859
-
-
Dreger, P.1
Dohner, H.2
McClanahan, F.3
Busch, R.4
Ritgen, M.5
Greinix, H.6
Fink, A.-M.7
Knauf, W.8
Stadler, M.9
Pfreundschuh, M.10
Duhrsen, U.11
Brittinger, G.12
Hensel, M.13
Schetelig, J.14
Winkler, D.15
Buhler, A.16
Kneba, M.17
Schmitz, N.18
Hallek, M.19
Stilgenbauer, S.20
more..
-
29
-
-
84879173666
-
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
-
Dreger, P., Schnaiter, A., Zenz, T., Bottcher, S., Rossi, M., Paschka, P., Buhler, A., Dietrich, S., Busch, R., Ritgen, M., Bunjes, D., Zeis, M., Stadler, M., Uharek, L., Scheid, C., Hegenbart, U., Hallek, M., Kneba, M., Schmitz, N., Dohner, H. & Stilgenbauer, S. (2013) TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood, 121, 3284-3288.
-
(2013)
Blood
, vol.121
, pp. 3284-3288
-
-
Dreger, P.1
Schnaiter, A.2
Zenz, T.3
Bottcher, S.4
Rossi, M.5
Paschka, P.6
Buhler, A.7
Dietrich, S.8
Busch, R.9
Ritgen, M.10
Bunjes, D.11
Zeis, M.12
Stadler, M.13
Uharek, L.14
Scheid, C.15
Hegenbart, U.16
Hallek, M.17
Kneba, M.18
Schmitz, N.19
Dohner, H.20
Stilgenbauer, S.21
more..
-
30
-
-
40849094878
-
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
-
Dungarwalla, M., Evans, S.O., Riley, U., Catovsky, D., Dearden, C.E. & Matutes, E. (2008) High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica, 93, 475-476.
-
(2008)
Haematologica
, vol.93
, pp. 475-476
-
-
Dungarwalla, M.1
Evans, S.O.2
Riley, U.3
Catovsky, D.4
Dearden, C.E.5
Matutes, E.6
-
31
-
-
31544434508
-
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
-
German CLL Study Group
-
Eichhorst, B.F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., Siehl, S., Jäger, U., Bergmann, M., Stilgenbauer, S., Schweighofer, C., Wendtner, C.M., Döhner, H., Brittinger, G., Emmerich, B., Hallek, M. & German CLL Study Group (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 107, 885-891.
-
(2006)
Blood
, vol.107
, pp. 885-891
-
-
Eichhorst, B.F.1
Busch, R.2
Hopfinger, G.3
Pasold, R.4
Hensel, M.5
Steinbrecher, C.6
Siehl, S.7
Jäger, U.8
Bergmann, M.9
Stilgenbauer, S.10
Schweighofer, C.11
Wendtner, C.M.12
Döhner, H.13
Brittinger, G.14
Emmerich, B.15
Hallek, M.16
-
32
-
-
80052716066
-
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
On behalf of the ESMO Guidelines Working Group
-
Eichhorst, B., Dreyling, M., Robak, T., Montserrat, E. & Hallek, M. On behalf of the ESMO Guidelines Working Group (2011) Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 22, vi50-vi54.
-
(2011)
Annals of Oncology
, vol.22
-
-
Eichhorst, B.1
Dreyling, M.2
Robak, T.3
Montserrat, E.4
Hallek, M.5
-
33
-
-
34249774066
-
Comprehensive geriatric assessment for older patients with cancer
-
Extermann, M. & Hurria, A. (2007) Comprehensive geriatric assessment for older patients with cancer. Journal of Clinical Oncology, 25, 1824-1831.
-
(2007)
Journal of Clinical Oncology
, vol.25
, pp. 1824-1831
-
-
Extermann, M.1
Hurria, A.2
-
34
-
-
45949100928
-
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
-
Ferrajoli, A., Lee, B.-N., Schlette, E.J., O'Brien, S.M., Gao, H., Wen, S., Wierda, W.G., Estrov, Z., Faderl, S., Cohen, E.N., Li, C., Reuben, J.M. & Keating, M.J. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 111, 5291-5297.
-
(2008)
Blood
, vol.111
, pp. 5291-5297
-
-
Ferrajoli, A.1
Lee, B.-N.2
Schlette, E.J.3
O'Brien, S.M.4
Gao, H.5
Wen, S.6
Wierda, W.G.7
Estrov, Z.8
Faderl, S.9
Cohen, E.N.10
Li, C.11
Reuben, J.M.12
Keating, M.J.13
-
35
-
-
80053020928
-
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
-
Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C.D., Bottcher, S., Staib, P., Kiehl, M., Eckart, M.J., Kranz, G., Goede, V., Elter, T., Buhler, A., Winkler, D., Kneba, M., Dohner, H., Eichhorst, B.F., Hallek, M. & Wendtner, C.-M. (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 29, 3559-3566.
-
(2011)
Journal of Clinical Oncology
, vol.29
, pp. 3559-3566
-
-
Fischer, K.1
Cramer, P.2
Busch, R.3
Stilgenbauer, S.4
Bahlo, J.5
Schweighofer, C.D.6
Bottcher, S.7
Staib, P.8
Kiehl, M.9
Eckart, M.J.10
Kranz, G.11
Goede, V.12
Elter, T.13
Buhler, A.14
Winkler, D.15
Kneba, M.16
Dohner, H.17
Eichhorst, B.F.18
Hallek, M.19
Wendtner, C.-M.20
more..
-
36
-
-
33947541773
-
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
-
Flinn, I.W., Neuberg, D.S., Grever, M.R., Dewald, G.W., Bennett, J.M., Paietta, E.M., Hussein, M.A., Appelbaum, F.R., Larson, R.A., Moore, D.F. & Tallman, M.S. (2007) Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology, 25, 793-798.
-
(2007)
Journal of Clinical Oncology
, vol.25
, pp. 793-798
-
-
Flinn, I.W.1
Neuberg, D.S.2
Grever, M.R.3
Dewald, G.W.4
Bennett, J.M.5
Paietta, E.M.6
Hussein, M.A.7
Appelbaum, F.R.8
Larson, R.A.9
Moore, D.F.10
Tallman, M.S.11
-
37
-
-
38349084386
-
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
-
Gattei, V., Bulian, P., Del Principe, M.I., Zucchetto, A., Maurillo, L., Buccisano, F., Bomben, R., Dal-Bo, M., Luciano, F., Rossi, F.M., Degan, M., Amadori, S. & Del Poeta, G. (2008) Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood, 111, 865-873.
-
(2008)
Blood
, vol.111
, pp. 865-873
-
-
Gattei, V.1
Bulian, P.2
Del Principe, M.I.3
Zucchetto, A.4
Maurillo, L.5
Buccisano, F.6
Bomben, R.7
Dal-Bo, M.8
Luciano, F.9
Rossi, F.M.10
Degan, M.11
Amadori, S.12
Del Poeta, G.13
-
38
-
-
77953811725
-
Cancer stem cells: back to Darwin?
-
Greaves, M. (2010) Cancer stem cells: back to Darwin? Seminars in Cancer Biology, 20, 65-70.
-
(2010)
Seminars in Cancer Biology
, vol.20
, pp. 65-70
-
-
Greaves, M.1
-
40
-
-
45149100665
-
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
-
International Workshop on Chronic Lymphocytic Leukemia
-
Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R., Kipps, T.J. & International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
-
(2008)
Blood
, vol.111
, pp. 5446-5456
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
Caligaris-Cappio, F.4
Dighiero, G.5
Döhner, H.6
Hillmen, P.7
Keating, M.J.8
Montserrat, E.9
Rai, K.R.10
Kipps, T.J.11
-
41
-
-
77957664665
-
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
-
On behalf of an International Group of Investigators and the German Chronic Lymphocytic Leukaemia Study Group
-
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., Grünhagen, von.U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H. & Stilgenbauer, S. On behalf of an International Group of Investigators and the German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
-
(2010)
Lancet
, vol.376
, pp. 1164-1174
-
-
Hallek, M.1
Fischer, K.2
Fingerle-Rowson, G.3
Fink, A.4
Busch, R.5
Mayer, J.6
Hensel, M.7
Hopfinger, G.8
Hess, G.9
Grünhagen, vonU.10
Bergmann, M.11
Catalano, J.12
Zinzani, P.L.13
Caligaris-Cappio, F.14
Seymour, J.15
Berrebi, A.16
Jager, U.17
Cazin, B.18
Trneny, M.19
Westermann, A.20
Wendtner, C.M.21
Eichhorst, B.F.22
Staib, P.23
Bühler, A.24
Winkler, D.25
Zenz, T.26
Böttcher, S.27
Ritgen, M.28
Mendila, M.29
Kneba, M.30
Döhner, H.31
Stilgenbauer, S.32
more..
-
42
-
-
33646477111
-
Autoimmune complications of chronic lymphocytic leukemia
-
Hamblin, T.J. (2006) Autoimmune complications of chronic lymphocytic leukemia. Seminars in Oncology, 33, 230-239.
-
(2006)
Seminars in Oncology
, vol.33
, pp. 230-239
-
-
Hamblin, T.J.1
-
43
-
-
84874542878
-
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
-
Hoogeboom, R., van Kessel, K.P.M., Hochstenbach, F., Wormhoudt, T.A., Reinten, R.J.A., Wagner, K., Kater, A.P., Guikema, J.E.J., Bende, R.J. & van Noesel, C.J.M. (2013) A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. Journal of Experimental Medicine, 210, 59-70.
-
(2013)
Journal of Experimental Medicine
, vol.210
, pp. 59-70
-
-
Hoogeboom, R.1
van Kessel, K.P.M.2
Hochstenbach, F.3
Wormhoudt, T.A.4
Reinten, R.J.A.5
Wagner, K.6
Kater, A.P.7
Guikema, J.E.J.8
Bende, R.J.9
van Noesel, C.J.M.10
-
44
-
-
0030687662
-
P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia
-
Johnston, J.B., Daeninck, P., Verburg, L., Lee, K., Williams, G., Israels, L.G., Mowat, M.R. & Begleiter, A. (1997) P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leukemia & Lymphoma, 26, 435-449.
-
(1997)
Leukemia & Lymphoma
, vol.26
, pp. 435-449
-
-
Johnston, J.B.1
Daeninck, P.2
Verburg, L.3
Lee, K.4
Williams, G.5
Israels, L.G.6
Mowat, M.R.7
Begleiter, A.8
-
45
-
-
68449102378
-
A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia
-
Kaufman, M., Limaye, S.A., Driscoll, N., Johnson, C., Caramanica, A., Lebowicz, Y., Patel, D., Kohn, N. & Rai, K. (2009) A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leukemia & Lymphoma, 50, 892-899.
-
(2009)
Leukemia & Lymphoma
, vol.50
, pp. 892-899
-
-
Kaufman, M.1
Limaye, S.A.2
Driscoll, N.3
Johnson, C.4
Caramanica, A.5
Lebowicz, Y.6
Patel, D.7
Kohn, N.8
Rai, K.9
-
46
-
-
0036335916
-
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia
-
Keating, M., O'Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C., Beran, M., Lerner, S. & Kantarjian, H. (2002a) Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia & Lymphoma, 43, 1755-1762.
-
(2002)
Leukemia & Lymphoma
, vol.43
, pp. 1755-1762
-
-
Keating, M.1
O'Brien, S.2
Kontoyiannis, D.3
Plunkett, W.4
Koller, C.5
Beran, M.6
Lerner, S.7
Kantarjian, H.8
-
47
-
-
0037092951
-
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
-
Keating, M.J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002b) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 3554-3561.
-
(2002)
Blood
, vol.99
, pp. 3554-3561
-
-
Keating, M.J.1
Flinn, I.2
Jain, V.3
Binet, J.-L.4
Hillmen, P.5
Byrd, J.6
Albitar, M.7
Brettman, L.8
Santabarbara, P.9
Wacker, B.10
Rai, K.R.11
-
48
-
-
77956263666
-
Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia
-
Keating, M.J., Wierda, W.G., Tam, C.S., Lynn, A., O'Brien, S., Lerner, S. & Kantarjian, H.M. (2009) Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), 114, 238.
-
(2009)
Blood (ASH Annual Meeting Abstracts)
, vol.114
, pp. 238
-
-
Keating, M.J.1
Wierda, W.G.2
Tam, C.S.3
Lynn, A.4
O'Brien, S.5
Lerner, S.6
Kantarjian, H.M.7
-
49
-
-
70349330220
-
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia
-
Knauf, W.U., Lissichkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Fricke, H.-J., Huguet, F., Del Giudice, I., Klein, P., Tremmel, L., Merkle, K. & Montillo, M. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 27, 4378-4384.
-
(2009)
Journal of Clinical Oncology
, vol.27
, pp. 4378-4384
-
-
Knauf, W.U.1
Lissichkov, T.2
Aldaoud, A.3
Liberati, A.4
Loscertales, J.5
Herbrecht, R.6
Juliusson, G.7
Postner, G.8
Gercheva, L.9
Goranov, S.10
Becker, M.11
Fricke, H.-J.12
Huguet, F.13
Del Giudice, I.14
Klein, P.15
Tremmel, L.16
Merkle, K.17
Montillo, M.18
-
50
-
-
84878898569
-
Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen
-
Kneba, M., Fischer, K., Bahlo, J., Fink, A.M., Busch, R., Bottcher, S., Dohner, H., Mayer, J., Dreger, P., Maurer, C., Engelke, A., Eichhorst, B.F., Wendtner, C.-M., Stilgenbauer, S. & Hallek, M. (2012) Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen. Blood (ASH Annual Meeting Abstracts), 120, 435.
-
(2012)
Blood (ASH Annual Meeting Abstracts)
, vol.120
, pp. 435
-
-
Kneba, M.1
Fischer, K.2
Bahlo, J.3
Fink, A.M.4
Busch, R.5
Bottcher, S.6
Dohner, H.7
Mayer, J.8
Dreger, P.9
Maurer, C.10
Engelke, A.11
Eichhorst, B.F.12
Wendtner, C.-M.13
Stilgenbauer, S.14
Hallek, M.15
-
51
-
-
84863785266
-
Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia
-
Knight, S.J.L., Yau, C., Clifford, R., Timbs, A.T., Sadighi Akha, E., Dréau, H.M., Burns, A., Ciria, C., Oscier, D.G., Pettitt, A.R., Dutton, S., Holmes, C.C., Taylor, J., Cazier, J.-B. & Schuh, A. (2012) Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia, 26, 1564-1575.
-
(2012)
Leukemia
, vol.26
, pp. 1564-1575
-
-
Knight, S.J.L.1
Yau, C.2
Clifford, R.3
Timbs, A.T.4
Sadighi Akha, E.5
Dréau, H.M.6
Burns, A.7
Ciria, C.8
Oscier, D.G.9
Pettitt, A.R.10
Dutton, S.11
Holmes, C.C.12
Taylor, J.13
Cazier, J.-B.14
Schuh, A.15
-
52
-
-
84874102335
-
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
-
Landau, D.A., Carter, S.L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M.S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., Wan, Y., Zhang, W., Shukla, S.A., Vartanov, A., Fernandes, S.M., Saksena, G., Cibulskis, K., Tesar, B., Gabriel, S., Hacohen, N., Meyerson, M., Lander, E.S., Neuberg, D., Brown, J.R., Getz, G. & Wu, C.J. (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell, 152, 714-726.
-
(2013)
Cell
, vol.152
, pp. 714-726
-
-
Landau, D.A.1
Carter, S.L.2
Stojanov, P.3
McKenna, A.4
Stevenson, K.5
Lawrence, M.S.6
Sougnez, C.7
Stewart, C.8
Sivachenko, A.9
Wang, L.10
Wan, Y.11
Zhang, W.12
Shukla, S.A.13
Vartanov, A.14
Fernandes, S.M.15
Saksena, G.16
Cibulskis, K.17
Tesar, B.18
Gabriel, S.19
Hacohen, N.20
Meyerson, M.21
Lander, E.S.22
Neuberg, D.23
Brown, J.R.24
Getz, G.25
Wu, C.J.26
more..
-
53
-
-
43549093570
-
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
-
Lanemo Myhrinder, A., Hellqvist, E., Sidorova, E., Söderberg, A., Baxendale, H., Dahle, C., Willander, K., Tobin, G., Bäckman, E., Söderberg, O., Rosenquist, R., Hörkkö, S. & Rosén, A. (2008) A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood, 111, 3838-3848.
-
(2008)
Blood
, vol.111
, pp. 3838-3848
-
-
Lanemo Myhrinder, A.1
Hellqvist, E.2
Sidorova, E.3
Söderberg, A.4
Baxendale, H.5
Dahle, C.6
Willander, K.7
Tobin, G.8
Bäckman, E.9
Söderberg, O.10
Rosenquist, R.11
Hörkkö, S.12
Rosén, A.13
-
54
-
-
78650017999
-
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101
-
Lin, T.S., Donohue, K.A., Byrd, J.C., Lucas, M.S., Hoke, E.E., Bengtson, E.M., Rai, K.R., Atkins, J.N., Link, B.K. & Larson, R.A. (2010) Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. Journal of Clinical Oncology, 28, 4500-4506.
-
(2010)
Journal of Clinical Oncology
, vol.28
, pp. 4500-4506
-
-
Lin, T.S.1
Donohue, K.A.2
Byrd, J.C.3
Lucas, M.S.4
Hoke, E.E.5
Bengtson, E.M.6
Rai, K.R.7
Atkins, J.N.8
Link, B.K.9
Larson, R.A.10
-
55
-
-
80051793679
-
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial
-
Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., Linch, D., Robinson, M., Jack, A. & Hoskin, P. (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and Oncology, 100, 86-92.
-
(2011)
Radiotherapy and Oncology
, vol.100
, pp. 86-92
-
-
Lowry, L.1
Smith, P.2
Qian, W.3
Falk, S.4
Benstead, K.5
Illidge, T.6
Linch, D.7
Robinson, M.8
Jack, A.9
Hoskin, P.10
-
56
-
-
0036683449
-
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
-
Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H. & Osterborg, A. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, 768-773.
-
(2002)
Blood
, vol.100
, pp. 768-773
-
-
Lundin, J.1
Kimby, E.2
Bjorkholm, M.3
Broliden, P.4
Celsing, F.5
Hjalmar, V.6
Mollgard, L.7
Rebello, P.8
Hale, G.9
Waldmann, H.10
Mellstedt, H.11
Osterborg, A.12
-
57
-
-
79955601718
-
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL
-
Majid, A., Lin, T.T., Best, G., Fishlock, K., Hewamana, S., Pratt, G., Yallop, D., Buggins, A.G.S., Wagner, S., Kennedy, B.J., Miall, F., Hills, R., Devereux, S., Oscier, D.G., Dyer, M.J.S., Fegan, C. & Pepper, C. (2011) CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leukemia Research, 35, 750-756.
-
(2011)
Leukemia Research
, vol.35
, pp. 750-756
-
-
Majid, A.1
Lin, T.T.2
Best, G.3
Fishlock, K.4
Hewamana, S.5
Pratt, G.6
Yallop, D.7
Buggins, A.G.S.8
Wagner, S.9
Kennedy, B.J.10
Miall, F.11
Hills, R.12
Devereux, S.13
Oscier, D.G.14
Dyer, M.J.S.15
Fegan, C.16
Pepper, C.17
-
58
-
-
20044372326
-
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
-
Messmer, B.T., Messmer, D., Allen, S.L., Kolitz, J.E., Kudalkar, P., Cesar, D., Murphy, E.J., Koduru, P., Ferrarini, M., Zupo, S., Cutrona, G., Damle, R.N., Wasil, T., Rai, K.R., Hellerstein, M.K. & Chiorazzi, N. (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. The Journal of Clinical Investigation, 115, 755-764.
-
(2005)
The Journal of Clinical Investigation
, vol.115
, pp. 755-764
-
-
Messmer, B.T.1
Messmer, D.2
Allen, S.L.3
Kolitz, J.E.4
Kudalkar, P.5
Cesar, D.6
Murphy, E.J.7
Koduru, P.8
Ferrarini, M.9
Zupo, S.10
Cutrona, G.11
Damle, R.N.12
Wasil, T.13
Rai, K.R.14
Hellerstein, M.K.15
Chiorazzi, N.16
-
59
-
-
79551631475
-
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation
-
EBMT Chronic Leukemia Working Party
-
Michallet, M., Dreger, P., Sutton, L., Brand, R., Richards, S., van Os, M., Sobh, M., Choquet, S., Corront, B., Dearden, C., Gratwohl, A., Herr, W., Catovsky, D., Hallek, M., de Witte, T., Niederwieser, D., Leporrier, M., Milligan, D. & EBMT Chronic Leukemia Working Party (2011) Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood, 117, 1516-1521.
-
(2011)
Blood
, vol.117
, pp. 1516-1521
-
-
Michallet, M.1
Dreger, P.2
Sutton, L.3
Brand, R.4
Richards, S.5
van Os, M.6
Sobh, M.7
Choquet, S.8
Corront, B.9
Dearden, C.10
Gratwohl, A.11
Herr, W.12
Catovsky, D.13
Hallek, M.14
de Witte, T.15
Niederwieser, D.16
Leporrier, M.17
Milligan, D.18
-
60
-
-
84866152172
-
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
-
Minden, M.D.-V., Übelhart, R., Schneider, D., Wossning, T., Bach, M.P., Buchner, M., Hofmann, D., Surova, E., Follo, M., Köhler, F., Wardemann, H., Zirlik, K., Veelken, H. & Jumaa, H. (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature, 489, 309-312.
-
(2012)
Nature
, vol.489
, pp. 309-312
-
-
Minden, M.-V.1
Übelhart, R.2
Schneider, D.3
Wossning, T.4
Bach, M.P.5
Buchner, M.6
Hofmann, D.7
Surova, E.8
Follo, M.9
Köhler, F.10
Wardemann, H.11
Zirlik, K.12
Veelken, H.13
Jumaa, H.14
-
61
-
-
79959467722
-
Autografting CLL: the game is over!
-
Montserrat, E. & Gribben, J.G. (2011) Autografting CLL: the game is over! Blood, 117, 6057-6058.
-
(2011)
Blood
, vol.117
, pp. 6057-6058
-
-
Montserrat, E.1
Gribben, J.G.2
-
62
-
-
21144456107
-
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
-
Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S.M.B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A. & Hillmen, P. (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology, 23, 2971-2979.
-
(2005)
Journal of Clinical Oncology
, vol.23
, pp. 2971-2979
-
-
Moreton, P.1
Kennedy, B.2
Lucas, G.3
Leach, M.4
Rassam, S.M.B.5
Haynes, A.6
Tighe, J.7
Oscier, D.8
Fegan, C.9
Rawstron, A.10
Hillmen, P.11
-
63
-
-
0037106257
-
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
-
Morrison, V.A. (2002) Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. Journal of Clinical Oncology, 20, 3878-3884.
-
(2002)
Journal of Clinical Oncology
, vol.20
, pp. 3878-3884
-
-
Morrison, V.A.1
-
65
-
-
77951561987
-
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
-
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jäger, C., Strein, P., Fertig, G., Friess, T., Schüll, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M., Poppema, S., Klein, C. & Umana, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 115, 4393-4402.
-
(2010)
Blood
, vol.115
, pp. 4393-4402
-
-
Mössner, E.1
Brünker, P.2
Moser, S.3
Püntener, U.4
Schmidt, C.5
Herter, S.6
Grau, R.7
Gerdes, C.8
Nopora, A.9
van Puijenbroek, E.10
Ferrara, C.11
Sondermann, P.12
Jäger, C.13
Strein, P.14
Fertig, G.15
Friess, T.16
Schüll, C.17
Bauer, S.18
Dal Porto, J.19
Del Nagro, C.20
Dabbagh, K.21
Dyer, M.22
Poppema, S.23
Klein, C.24
Umana, P.25
more..
-
66
-
-
84886424411
-
A randomised dose de-escalation safety study of Oral Fludarabine, {+/-}Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years - end of recruitment analysis of response and toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
-
Mulligan, S.P., Gill, D.S., Turner, P., Renwick, W.E.P., Harrup, R., Latimer, M., Mackinlay, N., Berkahn, L., Simpson, D., Campbell, P., Tiley, C., Cull, G., Collins, M., Cortissos, P., Sulda, M., Best, G. & Kuss, B.J. (2012) A randomised dose de-escalation safety study of Oral Fludarabine, {+/-}Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years - end of recruitment analysis of response and toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood (ASH Annual Meeting Abstracts), 120, 436.
-
(2012)
Blood (ASH Annual Meeting Abstracts)
, vol.120
, pp. 436
-
-
Mulligan, S.P.1
Gill, D.S.2
Turner, P.3
Renwick, W.E.P.4
Harrup, R.5
Latimer, M.6
Mackinlay, N.7
Berkahn, L.8
Simpson, D.9
Campbell, P.10
Tiley, C.11
Cull, G.12
Collins, M.13
Cortissos, P.14
Sulda, M.15
Best, G.16
Kuss, B.J.17
-
67
-
-
0025872795
-
Karyotypic evolution in B-cell chronic lymphocytic leukaemia
-
Oscier, D., Fitchett, M., Herbert, T. & Lambert, R. (1991) Karyotypic evolution in B-cell chronic lymphocytic leukaemia. Genes Chromosomes Cancer, 3, 16-20.
-
(1991)
Genes Chromosomes Cancer
, vol.3
, pp. 16-20
-
-
Oscier, D.1
Fitchett, M.2
Herbert, T.3
Lambert, R.4
-
68
-
-
84869097175
-
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia
-
British Committee for Standards in Haematology
-
Oscier, D., Dearden, C., Erem, E., Fegan, C., Follows, G., Hillmen, P., Illidge, T., Matutes, E., Milligan, D.W., Pettitt, A., Schuh, A., Wimperis, J. & British Committee for Standards in Haematology (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. British Journal of Haematology, 159, 541-564.
-
(2012)
British Journal of Haematology
, vol.159
, pp. 541-564
-
-
Oscier, D.1
Dearden, C.2
Erem, E.3
Fegan, C.4
Follows, G.5
Hillmen, P.6
Illidge, T.7
Matutes, E.8
Milligan, D.W.9
Pettitt, A.10
Schuh, A.11
Wimperis, J.12
-
69
-
-
46749145421
-
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
-
Patten, P.E.M., Buggins, A.G.S., Richards, J., Wotherspoon, A., Salisbury, J., Mufti, G.J., Hamblin, T.J. & Devereux, S. (2008) CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood, 111, 5173-5181.
-
(2008)
Blood
, vol.111
, pp. 5173-5181
-
-
Patten, P.E.M.1
Buggins, A.G.S.2
Richards, J.3
Wotherspoon, A.4
Salisbury, J.5
Mufti, G.J.6
Hamblin, T.J.7
Devereux, S.8
-
70
-
-
33746137366
-
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
-
Pettitt, A.R., Matutes, E. & Oscier, D. (2006) Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia, 20, 1441-1445.
-
(2006)
Leukemia
, vol.20
, pp. 1441-1445
-
-
Pettitt, A.R.1
Matutes, E.2
Oscier, D.3
-
71
-
-
84863769805
-
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 trial
-
Pettitt, A.R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., Johnson, G.G., Schuh, A., Matutes, E., Dearden, C.E., Catovsky, D., Radford, J.A., Bloor, A., Follows, G.A., Devereux, S., Kruger, A., Blundell, J., Agrawal, S., Allsup, D., Proctor, S., Heartin, E., Oscier, D., Hamblin, T.J., Rawstron, A. & Hillmen, P. (2012) Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the National Cancer Research Institute CLL206 trial. Journal of Clinical Oncology, 30, 1647-1655.
-
(2012)
Journal of Clinical Oncology
, vol.30
, pp. 1647-1655
-
-
Pettitt, A.R.1
Jackson, R.2
Carruthers, S.3
Dodd, J.4
Dodd, S.5
Oates, M.6
Johnson, G.G.7
Schuh, A.8
Matutes, E.9
Dearden, C.E.10
Catovsky, D.11
Radford, J.A.12
Bloor, A.13
Follows, G.A.14
Devereux, S.15
Kruger, A.16
Blundell, J.17
Agrawal, S.18
Allsup, D.19
Proctor, S.20
Heartin, E.21
Oscier, D.22
Hamblin, T.J.23
Rawstron, A.24
Hillmen, P.25
more..
-
72
-
-
79957456534
-
Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia
-
Pileckyte, R., Jurgutis, M., Valceckiene, V., Stoskus, M., Gineikiene, E., Sejoniene, J., Degulys, A., Zvirblis, T. & Griskevicius, L. (2011) Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma, 52, 1055-1065.
-
(2011)
Leukemia & Lymphoma
, vol.52
, pp. 1055-1065
-
-
Pileckyte, R.1
Jurgutis, M.2
Valceckiene, V.3
Stoskus, M.4
Gineikiene, E.5
Sejoniene, J.6
Degulys, A.7
Zvirblis, T.8
Griskevicius, L.9
-
73
-
-
80051720194
-
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
-
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 365, 725-733.
-
(2011)
New England Journal of Medicine
, vol.365
, pp. 725-733
-
-
Porter, D.L.1
Levine, B.L.2
Kalos, M.3
Bagg, A.4
June, C.H.5
-
74
-
-
68449089448
-
Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis
-
Raanani, P., Gafter-Gvili, A., Paul, M., Ben-Bassat, I., Leibovici, L. & Shpilberg, O. (2009) Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leukemia & Lymphoma, 50, 764-772.
-
(2009)
Leukemia & Lymphoma
, vol.50
, pp. 764-772
-
-
Raanani, P.1
Gafter-Gvili, A.2
Paul, M.3
Ben-Bassat, I.4
Leibovici, L.5
Shpilberg, O.6
-
75
-
-
77950478885
-
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia
-
Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Geisler, C.H., Montillo, M., Zyuzgin, I., Ganly, P.S., Dartigeas, C., Rosta, A., Maurer, J., Mendila, M., Saville, M.W., Valente, N., Wenger, M.K. & Moiseev, S.I. (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1756-1765.
-
(2010)
Journal of Clinical Oncology
, vol.28
, pp. 1756-1765
-
-
Robak, T.1
Dmoszynska, A.2
Solal-Céligny, P.3
Warzocha, K.4
Loscertales, J.5
Catalano, J.6
Afanasiev, B.V.7
Larratt, L.8
Geisler, C.H.9
Montillo, M.10
Zyuzgin, I.11
Ganly, P.S.12
Dartigeas, C.13
Rosta, A.14
Maurer, J.15
Mendila, M.16
Saville, M.W.17
Valente, N.18
Wenger, M.K.19
Moiseev, S.I.20
more..
-
76
-
-
84255160977
-
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
-
Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., Guarini, A., Del Giudice, I., Cerri, M., Cresta, S., Deambrogi, C., Gargiulo, E., Gattei, V., Forconi, F., Bertoni, F., Deaglio, S., Rabadan, R., Pasqualucci, L., Foà, R., Dalla-Favera, R. & Gaidano, G. (2011a) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood, 118, 6904-6908.
-
(2011)
Blood
, vol.118
, pp. 6904-6908
-
-
Rossi, D.1
Bruscaggin, A.2
Spina, V.3
Rasi, S.4
Khiabanian, H.5
Messina, M.6
Fangazio, M.7
Vaisitti, T.8
Monti, S.9
Chiaretti, S.10
Guarini, A.11
Del Giudice, I.12
Cerri, M.13
Cresta, S.14
Deambrogi, C.15
Gargiulo, E.16
Gattei, V.17
Forconi, F.18
Bertoni, F.19
Deaglio, S.20
Rabadan, R.21
Pasqualucci, L.22
Foà, R.23
Dalla-Favera, R.24
Gaidano, G.25
more..
-
77
-
-
79953117852
-
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
-
Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., Arcaini, L., Lucioni, M., Rocque, G.B., Xu-Monette, Z.Y., Visco, C., Chang, J., Chigrinova, E., Forconi, F., Marasca, R., Besson, C., Papadaki, T., Paulli, M., Larocca, L.M., Pileri, S.A., Gattei, V., Bertoni, F., Foà, R., Young, K.H. & Gaidano, G. (2011b) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood, 117, 3391-3401.
-
(2011)
Blood
, vol.117
, pp. 3391-3401
-
-
Rossi, D.1
Spina, V.2
Deambrogi, C.3
Rasi, S.4
Laurenti, L.5
Stamatopoulos, K.6
Arcaini, L.7
Lucioni, M.8
Rocque, G.B.9
Xu-Monette, Z.Y.10
Visco, C.11
Chang, J.12
Chigrinova, E.13
Forconi, F.14
Marasca, R.15
Besson, C.16
Papadaki, T.17
Paulli, M.18
Larocca, L.M.19
Pileri, S.A.20
Gattei, V.21
Bertoni, F.22
Foà, R.23
Young, K.H.24
Gaidano, G.25
more..
-
78
-
-
84874428346
-
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
-
Rossi, D., Rasi, S., Spina, V., Bruscaggin, A., Monti, S., Ciardullo, C., Deambrogi, C., Khiabanian, H., Serra, R., Bertoni, F., Forconi, F., Laurenti, L., Marasca, R., Dal-Bo, M., Rossi, F.M., Bulian, P., Nomdedeu, J., Del Poeta, G., Gattei, V., Pasqualucci, L., Rabadan, R., Foà, R., Dalla-Favera, R. & Gaidano, G. (2013) Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood, 121, 1403-1412.
-
(2013)
Blood
, vol.121
, pp. 1403-1412
-
-
Rossi, D.1
Rasi, S.2
Spina, V.3
Bruscaggin, A.4
Monti, S.5
Ciardullo, C.6
Deambrogi, C.7
Khiabanian, H.8
Serra, R.9
Bertoni, F.10
Forconi, F.11
Laurenti, L.12
Marasca, R.13
Dal-Bo, M.14
Rossi, F.M.15
Bulian, P.16
Nomdedeu, J.17
Del Poeta, G.18
Gattei, V.19
Pasqualucci, L.20
Rabadan, R.21
Foà, R.22
Dalla-Favera, R.23
Gaidano, G.24
more..
-
79
-
-
0017730147
-
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia
-
Sawitsky, A., Rai, K.R., Glidewell, O. & Silver, R.T. (1977) Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood, 50, 1049-1059.
-
(1977)
Blood
, vol.50
, pp. 1049-1059
-
-
Sawitsky, A.1
Rai, K.R.2
Glidewell, O.3
Silver, R.T.4
-
80
-
-
55549097826
-
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis
-
Schetelig, J., van Biezen, A., Brand, R., Caballero, D., Martino, R., Itala, M., García-Marco, J.A., Volin, L., Schmitz, N., Schwerdtfeger, R., Ganser, A., Onida, F., Mohr, B., Stilgenbauer, S., Bornhäuser, M., de Witte, T. & Dreger, P. (2008) Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. Journal of Clinical Oncology, 26, 5094-5100.
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 5094-5100
-
-
Schetelig, J.1
van Biezen, A.2
Brand, R.3
Caballero, D.4
Martino, R.5
Itala, M.6
García-Marco, J.A.7
Volin, L.8
Schmitz, N.9
Schwerdtfeger, R.10
Ganser, A.11
Onida, F.12
Mohr, B.13
Stilgenbauer, S.14
Bornhäuser, M.15
de Witte, T.16
Dreger, P.17
-
81
-
-
84869753284
-
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
-
Schuh, A., Becq, J., Humphray, S., Alexa, A., Burns, A., Clifford, R., Feller, S.M., Grocock, R., Henderson, S., Khrebtukova, I., Kingsbury, Z., Luo, S., McBride, D., Murray, L., Menju, T., Timbs, A., Ross, M., Taylor, J. & Bentley, D. (2012) Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood, 120, 4191-4196.
-
(2012)
Blood
, vol.120
, pp. 4191-4196
-
-
Schuh, A.1
Becq, J.2
Humphray, S.3
Alexa, A.4
Burns, A.5
Clifford, R.6
Feller, S.M.7
Grocock, R.8
Henderson, S.9
Khrebtukova, I.10
Kingsbury, Z.11
Luo, S.12
McBride, D.13
Murray, L.14
Menju, T.15
Timbs, A.16
Ross, M.17
Taylor, J.18
Bentley, D.19
-
82
-
-
33750577939
-
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
-
Shanafelt, T.D. (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 4634-4641.
-
(2006)
Journal of Clinical Oncology
, vol.24
, pp. 4634-4641
-
-
Shanafelt, T.D.1
-
84
-
-
84880276168
-
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
-
Shanafelt, T.D., Ramsay, A.G., Zent, C.S., Leis, J.F., Tun, H.W., Call, T.G., Laplant, B., Bowen, D., Pettinger, A., Jelinek, D.F., Hanson, C.A. & Kay, N.E. (2013) Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood, 121, 4137-4141.
-
(2013)
Blood
, vol.121
, pp. 4137-4141
-
-
Shanafelt, T.D.1
Ramsay, A.G.2
Zent, C.S.3
Leis, J.F.4
Tun, H.W.5
Call, T.G.6
Laplant, B.7
Bowen, D.8
Pettinger, A.9
Jelinek, D.F.10
Hanson, C.A.11
Kay, N.E.12
-
85
-
-
84871798242
-
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial
-
Skowronska, A., Parker, A., Ahmed, G., Oldreive, C., Davis, Z., Richards, S., Dyer, M., Matutes, E., Gonzalez, D., Taylor, A.M.R., Moss, P., Thomas, P., Oscier, D. & Stankovic, T. (2012) Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. Journal of Clinical Oncology, 30, 4524-4532.
-
(2012)
Journal of Clinical Oncology
, vol.30
, pp. 4524-4532
-
-
Skowronska, A.1
Parker, A.2
Ahmed, G.3
Oldreive, C.4
Davis, Z.5
Richards, S.6
Dyer, M.7
Matutes, E.8
Gonzalez, D.9
Taylor, A.M.R.10
Moss, P.11
Thomas, P.12
Oscier, D.13
Stankovic, T.14
-
86
-
-
54449093967
-
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
-
Sorror, M.L., Storer, B.E., Sandmaier, B.M., Maris, M., Shizuru, J., Maziarz, R., Agura, E., Chauncey, T.R., Pulsipher, M.A., McSweeney, P.A., Wade, J.C., Bruno, B., Langston, A., Radich, J., Niederwieser, D., Blume, K.G., Storb, R. & Maloney, D.G. (2008) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Journal of Clinical Oncology, 26, 4912-4920.
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 4912-4920
-
-
Sorror, M.L.1
Storer, B.E.2
Sandmaier, B.M.3
Maris, M.4
Shizuru, J.5
Maziarz, R.6
Agura, E.7
Chauncey, T.R.8
Pulsipher, M.A.9
McSweeney, P.A.10
Wade, J.C.11
Bruno, B.12
Langston, A.13
Radich, J.14
Niederwieser, D.15
Blume, K.G.16
Storb, R.17
Maloney, D.G.18
-
87
-
-
84873540049
-
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
-
Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, S.L., Catron, N.D., Chen, J., Dayton, B.D., Ding, H., Enschede, S.H., Fairbrother, W.J., Huang, D.C.S., Hymowitz, S.G., Jin, S., Khaw, S.L., Kovar, P.J., Lam, L.T., Lee, J., Maecker, H.L., Marsh, K.C., Mason, K.D., Mitten, M.J., Nimmer, P.D., Oleksijew, A., Park, C.H., Park, C-M., Phillips, D.C., Roberts, A.W., Sampath, D., Seymour, J.F., Smith, M.L., Sullivan, G.M., Tahir, S.K., Tse, C., Wendt, M.D., Xiao, Y., Xue, J.C., Zhang, H., Humerickhouse, R.A., Rosenberg, S.H. & Elmore, S.W. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature medicine, 19, 202-208.
-
(2013)
Nature medicine
, vol.19
, pp. 202-208
-
-
Souers, A.J.1
Leverson, J.D.2
Boghaert, E.R.3
Ackler, S.L.4
Catron, N.D.5
Chen, J.6
Dayton, B.D.7
Ding, H.8
Enschede, S.H.9
Fairbrother, W.J.10
Huang, D.C.S.11
Hymowitz, S.G.12
Jin, S.13
Khaw, S.L.14
Kovar, P.J.15
Lam, L.T.16
Lee, J.17
Maecker, H.L.18
Marsh, K.C.19
Mason, K.D.20
Mitten, M.J.21
Nimmer, P.D.22
Oleksijew, A.23
Park, C.H.24
Park, C.-M.25
Phillips, D.C.26
Roberts, A.W.27
Sampath, D.28
Seymour, J.F.29
Smith, M.L.30
Sullivan, G.M.31
Tahir, S.K.32
Tse, C.33
Wendt, M.D.34
Xiao, Y.35
Xue, J.C.36
Zhang, H.37
Humerickhouse, R.A.38
Rosenberg, S.H.39
Elmore, S.W.40
more..
-
88
-
-
80054853285
-
B-cell receptor signaling in chronic lymphocytic leukemia
-
Stevenson, F.K., Krysov, S., Davies, A.J., Steele, A.J. & Packham, G. (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood, 118, 4313-4320.
-
(2011)
Blood
, vol.118
, pp. 4313-4320
-
-
Stevenson, F.K.1
Krysov, S.2
Davies, A.J.3
Steele, A.J.4
Packham, G.5
-
89
-
-
69849107362
-
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group
-
German Chronic Lymphocytic Leukemia Study Group
-
Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R.F., Groner, S., Busch, R., Hensel, M., Dührsen, U., Finke, J., Dreger, P., Jäger, U., Lengfelder, E., Hohloch, K., Söling, U., Schlag, R., Kneba, M., Hallek, M., Döhner, H. & German Chronic Lymphocytic Leukemia Study Group (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 27, 3994-4001.
-
(2009)
Journal of Clinical Oncology
, vol.27
, pp. 3994-4001
-
-
Stilgenbauer, S.1
Zenz, T.2
Winkler, D.3
Buhler, A.4
Schlenk, R.F.5
Groner, S.6
Busch, R.7
Hensel, M.8
Dührsen, U.9
Finke, J.10
Dreger, P.11
Jäger, U.12
Lengfelder, E.13
Hohloch, K.14
Söling, U.15
Schlag, R.16
Kneba, M.17
Hallek, M.18
Döhner, H.19
-
90
-
-
84861343178
-
Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: interim analysis of a phase II study of the GCLLSG and FCGCLL/MW
-
Stilgenbauer, S., Cymbalista, F., Leblond, V., Delmer, A., Winkler, D., Buhler, A., Zenz, T., Mack, S., Busch, R., Hinke, A., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Rieger, M., Alt, J., Sökler, M., Schetelig, J., Dreger, P., Hallek, M. & Döhner, H. (2011) Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: interim analysis of a phase II study of the GCLLSG and FCGCLL/MW. Blood (ASH Annual Meeting Abstracts), 118, 2854.
-
(2011)
Blood (ASH Annual Meeting Abstracts)
, vol.118
, pp. 2854
-
-
Stilgenbauer, S.1
Cymbalista, F.2
Leblond, V.3
Delmer, A.4
Winkler, D.5
Buhler, A.6
Zenz, T.7
Mack, S.8
Busch, R.9
Hinke, A.10
Choquet, S.11
Dartigeas, C.12
Cazin, B.13
Tournilhac, O.14
Rieger, M.15
Alt, J.16
Sökler, M.17
Schetelig, J.18
Dreger, P.19
Hallek, M.20
Döhner, H.21
more..
-
91
-
-
0036122035
-
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma
-
Summerfield, G.P., Taylor, P.R.A., Mounter, P.J. & Proctor, S.J. (2002) High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma. British Journal of Haematology, 116, 781-786.
-
(2002)
British Journal of Haematology
, vol.116
, pp. 781-786
-
-
Summerfield, G.P.1
Taylor, P.R.A.2
Mounter, P.J.3
Proctor, S.J.4
-
92
-
-
33750958028
-
Treatment-related myelodysplasia following fludarabine combination chemotherapy
-
Tam, C.S., Seymour, J.F., Prince, H.M., Kenealy, M., Wolf, M., Januszewicz, E.H. & Westerman, D. (2006) Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica, 91, 1546-1550.
-
(2006)
Haematologica
, vol.91
, pp. 1546-1550
-
-
Tam, C.S.1
Seymour, J.F.2
Prince, H.M.3
Kenealy, M.4
Wolf, M.5
Januszewicz, E.H.6
Westerman, D.7
-
93
-
-
35148849255
-
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
-
Tam, C.S., O'Brien, S., Lerner, S., Khouri, I., Ferrajoli, A., Faderl, S., Browning, M., Tsimberidou, A.M., Kantarjian, H. & Wierda, W.G. (2007) The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leukemia & Lymphoma, 48, 1931-1939.
-
(2007)
Leukemia & Lymphoma
, vol.48
, pp. 1931-1939
-
-
Tam, C.S.1
O'Brien, S.2
Lerner, S.3
Khouri, I.4
Ferrajoli, A.5
Faderl, S.6
Browning, M.7
Tsimberidou, A.M.8
Kantarjian, H.9
Wierda, W.G.10
-
94
-
-
4444343395
-
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
-
Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P.W.H.I., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G.J. & Glennie, M.J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104, 1793-1800.
-
(2004)
Blood
, vol.104
, pp. 1793-1800
-
-
Teeling, J.L.1
French, R.R.2
Cragg, M.S.3
van den Brakel, J.4
Pluyter, M.5
Huang, H.6
Chan, C.7
Parren, P.W.H.I.8
Hack, C.E.9
Dechant, M.10
Valerius, T.11
van de Winkel, J.G.J.12
Glennie, M.J.13
-
95
-
-
0346258157
-
High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
-
Thornton, P.D., Matutes, E., Bosanquet, A.G., Lakhani, A.K., Grech, H., Ropner, J.E., Joshi, R., Mackie, P.H., Douglas, I.D.C., Bowcock, S.J. & Catovsky, D. (2003) High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Annals of Hematology, 82, 759-765.
-
(2003)
Annals of Hematology
, vol.82
, pp. 759-765
-
-
Thornton, P.D.1
Matutes, E.2
Bosanquet, A.G.3
Lakhani, A.K.4
Grech, H.5
Ropner, J.E.6
Joshi, R.7
Mackie, P.H.8
Douglas, I.D.C.9
Bowcock, S.J.10
Catovsky, D.11
-
96
-
-
0037089334
-
The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes
-
Till, K., Lin, K., Zuzel, M. & Cawley, J. (2002) The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood, 99, 2977-2984.
-
(2002)
Blood
, vol.99
, pp. 2977-2984
-
-
Till, K.1
Lin, K.2
Zuzel, M.3
Cawley, J.4
-
97
-
-
33744800308
-
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
-
Tsimberidou, A.-M., O'Brien, S., Khouri, I., Giles, F.J., Kantarjian, H.M., Champlin, R., Wen, S., Do, K.-A., Smith, S.C., Lerner, S., Freireich, E.J. & Keating, M.J. (2006) Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. Journal of Clinical Oncology, 24, 2343-2351.
-
(2006)
Journal of Clinical Oncology
, vol.24
, pp. 2343-2351
-
-
Tsimberidou, A.-M.1
O'Brien, S.2
Khouri, I.3
Giles, F.J.4
Kantarjian, H.M.5
Champlin, R.6
Wen, S.7
Do, K.-A.8
Smith, S.C.9
Lerner, S.10
Freireich, E.J.11
Keating, M.J.12
-
98
-
-
38349163290
-
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
-
Tsimberidou, A.M., Wierda, W.G., Plunkett, W., Kurzrock, R., O'Brien, S., Wen, S., Ferrajoli, A., Ravandi-Kashani, F., Garcia-Manero, G., Estrov, Z., Kipps, T.J., Brown, J.R., Fiorentino, A., Lerner, S., Kantarjian, H.M. & Keating, M.J. (2008) Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 26, 196-203.
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 196-203
-
-
Tsimberidou, A.M.1
Wierda, W.G.2
Plunkett, W.3
Kurzrock, R.4
O'Brien, S.5
Wen, S.6
Ferrajoli, A.7
Ravandi-Kashani, F.8
Garcia-Manero, G.9
Estrov, Z.10
Kipps, T.J.11
Brown, J.R.12
Fiorentino, A.13
Lerner, S.14
Kantarjian, H.M.15
Keating, M.J.16
-
99
-
-
84886415663
-
NCRN CLL207 study of alemtuzumab consolidation in CLL: final response assessment and early follow-up (on behalf of the NCRI CLL Trials Sub-Group)
-
Varghese, A.M., Cohen, D., Pocock, C.F., Rawstron, A., Gregory, W.M., Smith, A., Skinner, E., Critchley, A., Milligan, D., Dearden, C.E., McCarthy, H., Fegan, C., Follows, G.A. & Hillmen, P. (2010) NCRN CLL207 study of alemtuzumab consolidation in CLL: final response assessment and early follow-up (on behalf of the NCRI CLL Trials Sub-Group). Blood (ASH Annual Meeting Abstracts), 116, 60.
-
(2010)
Blood (ASH Annual Meeting Abstracts)
, vol.116
, pp. 60
-
-
Varghese, A.M.1
Cohen, D.2
Pocock, C.F.3
Rawstron, A.4
Gregory, W.M.5
Smith, A.6
Skinner, E.7
Critchley, A.8
Milligan, D.9
Dearden, C.E.10
McCarthy, H.11
Fegan, C.12
Follows, G.A.13
Hillmen, P.14
-
100
-
-
0042236345
-
Mechanism of action and resistance to monoclonal antibody therapy
-
Villamor, N., Montserrat, E. & Colomer, D. (2003) Mechanism of action and resistance to monoclonal antibody therapy. Seminars in Oncology, 30, 424-433.
-
(2003)
Seminars in Oncology
, vol.30
, pp. 424-433
-
-
Villamor, N.1
Montserrat, E.2
Colomer, D.3
-
101
-
-
84878396846
-
SF3B1 mutations in chronic lymphocytic leukemia
-
Wan, Y. & Wu, C.J. (2013) SF3B1 mutations in chronic lymphocytic leukemia. Blood, 121, 4627-4634.
-
(2013)
Blood
, vol.121
, pp. 4627-4634
-
-
Wan, Y.1
Wu, C.J.2
-
102
-
-
84863115505
-
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
-
Wendtner, C.-M., Hillmen, P., Mahadevan, D., Buhler, A., Uharek, L., Coutré, S., Frankfurt, O., Bloor, A., Bosch, F., Furman, R.R., Kimby, E., Gribben, J.G., Gobbi, M., Dreisbach, L., Hurd, D.D., Sekeres, M.A., Ferrajoli, A., Shah, S., Zhang, J., Moutouh-de Parseval, L., Hallek, M., Heerema, N.A., Stilgenbauer, S. & Chanan-Khan, A.A. (2012) Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma, 53, 417-423.
-
(2012)
Leukemia & Lymphoma
, vol.53
, pp. 417-423
-
-
Wendtner, C.-M.1
Hillmen, P.2
Mahadevan, D.3
Buhler, A.4
Uharek, L.5
Coutré, S.6
Frankfurt, O.7
Bloor, A.8
Bosch, F.9
Furman, R.R.10
Kimby, E.11
Gribben, J.G.12
Gobbi, M.13
Dreisbach, L.14
Hurd, D.D.15
Sekeres, M.A.16
Ferrajoli, A.17
Shah, S.18
Zhang, J.19
Moutouh-de Parseval, L.20
Hallek, M.21
Heerema, N.A.22
Stilgenbauer, S.23
Chanan-Khan, A.A.24
more..
-
103
-
-
23044501404
-
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
-
Wierda, W., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.-A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H. & Keating, M. (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4070-4078.
-
(2005)
Journal of Clinical Oncology
, vol.23
, pp. 4070-4078
-
-
Wierda, W.1
O'Brien, S.2
Wen, S.3
Faderl, S.4
Garcia-Manero, G.5
Thomas, D.6
Do, K.-A.7
Cortes, J.8
Koller, C.9
Beran, M.10
Ferrajoli, A.11
Giles, F.12
Lerner, S.13
Albitar, M.14
Kantarjian, H.15
Keating, M.16
-
104
-
-
77950502126
-
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
-
Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J.S., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.
-
(2010)
Journal of Clinical Oncology
, vol.28
, pp. 1749-1755
-
-
Wierda, W.G.1
Kipps, T.J.2
Mayer, J.3
Stilgenbauer, S.4
Williams, C.D.5
Hellmann, A.6
Robak, T.7
Furman, R.R.8
Hillmen, P.9
Trneny, M.10
Dyer, M.J.S.11
Padmanabhan, S.12
Piotrowska, M.13
Kozak, T.14
Chan, G.15
Davis, R.16
Losic, N.17
Wilms, J.18
Russell, C.A.19
Osterborg, A.20
more..
-
105
-
-
84865176364
-
The B-cell receptor signaling pathway as a therapeutic target in CLL
-
Woyach, J.A., Johnson, A.J. & Byrd, J.C. (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood, 120, 1175-1184.
-
(2012)
Blood
, vol.120
, pp. 1175-1184
-
-
Woyach, J.A.1
Johnson, A.J.2
Byrd, J.C.3
-
106
-
-
33644545429
-
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
-
Yeo, W. & Johnson, P.J. (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology (Baltimore, MD), 43, 209-220.
-
(2006)
Hepatology (Baltimore, MD)
, vol.43
, pp. 209-220
-
-
Yeo, W.1
Johnson, P.J.2
-
107
-
-
70350511471
-
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
-
Zenz, T., Häbe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Döhner, H. & Stilgenbauer, S. (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 2589-2597.
-
(2009)
Blood
, vol.114
, pp. 2589-2597
-
-
Zenz, T.1
Häbe, S.2
Denzel, T.3
Mohr, J.4
Winkler, D.5
Buhler, A.6
Sarno, A.7
Groner, S.8
Mertens, D.9
Busch, R.10
Hallek, M.11
Döhner, H.12
Stilgenbauer, S.13
-
108
-
-
79957520824
-
Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLL8 Trial of the GCLLSG
-
Zenz, T., Busch, R., Fink, A., Winkler, D., Fischer, K., Buhler, A., Dohner, H., Hoth, P., Fingerle-Rowson, G.R., Kneba, M., Boettcher, S., Jager, U., Mendila, M., Wenger, M., Lichter, P., Hallek, M. & Stilgenbauer, S. (2010) Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLL8 Trial of the GCLLSG. Blood (ASH Annual Meeting Abstracts), 116, 2427.
-
(2010)
Blood (ASH Annual Meeting Abstracts)
, vol.116
, pp. 2427
-
-
Zenz, T.1
Busch, R.2
Fink, A.3
Winkler, D.4
Fischer, K.5
Buhler, A.6
Dohner, H.7
Hoth, P.8
Fingerle-Rowson, G.R.9
Kneba, M.10
Boettcher, S.11
Jager, U.12
Mendila, M.13
Wenger, M.14
Lichter, P.15
Hallek, M.16
Stilgenbauer, S.17
-
109
-
-
84860773361
-
Risk categories and refractory CLL in the era of chemoimmunotherapy
-
Zenz, T., Gribben, J.G., Hallek, M., Dohner, H., Keating, M.J. & Stilgenbauer, S. (2012) Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood, 119, 4101-4107.
-
(2012)
Blood
, vol.119
, pp. 4101-4107
-
-
Zenz, T.1
Gribben, J.G.2
Hallek, M.3
Dohner, H.4
Keating, M.J.5
Stilgenbauer, S.6
-
110
-
-
84856553821
-
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
-
Zhou, Y., Tang, G., Medeiros, L.J., McDonnell, T.J., Keating, M.J., Wierda, W.G. & Wang, S.A. (2012) Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Modern Pathology, 25, 237-245.
-
(2012)
Modern Pathology
, vol.25
, pp. 237-245
-
-
Zhou, Y.1
Tang, G.2
Medeiros, L.J.3
McDonnell, T.J.4
Keating, M.J.5
Wierda, W.G.6
Wang, S.A.7
|